Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Transplant Proc ; 51(1): 229-234, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30661897

RESUMO

Rhodococcus equi is a gram-positive coccobacillus responsible for severe infections in patients with weakened immune systems. R equi generally causes pnumonia that may evolve into fatal systemic infection if left untreated. Here, we present a case of a 67-year-old woman affected by acute intermittent porphyria (AIP) who developed R equi pneumonia 7 months after kidney transplantation. Although clinical features at presentation were nonspecific, lung computed tomography showed right perihilar consolidation with a mass-like appearance causing bronchial obstruction. Appropriate antibiotic including intravenous meropenem and oral azithromycin that was then switched to oral levofloxacin and oral azithromycin along with reduction of immunosuppressive therapy resolved pneumonia without provoking an acute attack of porphyria. AIP limited the choice of antibiotics for the treatment of R equi infection because some potentially porphyrinogenic antibacterial agents were avoided. Based on this experience, azithromycin and meropenem can be safely administered for the treatment of R Equi infection in patients with AIP.


Assuntos
Infecções por Actinomycetales/tratamento farmacológico , Infecções por Actinomycetales/imunologia , Antibacterianos/uso terapêutico , Transplante de Rim , Porfiria Aguda Intermitente/complicações , Infecções por Actinomycetales/complicações , Idoso , Azitromicina/uso terapêutico , Quimioterapia Combinada , Feminino , Humanos , Hospedeiro Imunocomprometido , Transplante de Rim/efeitos adversos , Levofloxacino/uso terapêutico , Meropeném/uso terapêutico , Pneumonia Bacteriana/imunologia , Pneumonia Bacteriana/microbiologia , Rhodococcus equi , Tomografia Computadorizada por Raios X , Transplantados
2.
Transplant Proc ; 50(3): 905-909, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29573830

RESUMO

Mucormycosis is an uncommonly encountered fungal infection in solid organ transplantation. The infection is severe and often results in a fatal outcome. The most common presentations are rhino-sino-orbital and pulmonary disease. We describe a rare case of gastric mucormycosis in a patient with a combined liver-kidney transplant affected by glycogen storage disease type Ia. A 42-year-old female patient presented with gastric pain and melena 26 days after transplantation. Evaluation with upper endoscopy showed two bleeding gastric ulcers. Histological examination of gastric specimens revealed fungal hyphae with evidence of Mucormycetes at subsequent molecular analysis. Immunosuppressive therapy was reduced and antifungal therapy consisting of liposomal amphotericin B and posaconazole was promptly introduced. Gastrointestinal side effects of posaconazole and acute T-cell rejection of renal graft complicated management of the case. A prolonged course of daily injections of amphotericin B together with a slight increase of immunosuppression favored successful treatment of mucormycosis as well as of graft rejection. At 2-year follow-up, the woman was found to have maintained normal renal and liver function. We conclude that judicious personalization of antimicrobial and antirejection therapy should be considered to resolve every life-threatening case of mucormycosis in solid organ transplantation.


Assuntos
Hospedeiro Imunocomprometido , Transplante de Rim , Transplante de Fígado , Mucormicose/imunologia , Gastropatias/imunologia , Adulto , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Feminino , Humanos , Transplante de Rim/efeitos adversos , Transplante de Fígado/efeitos adversos , Mucormicose/tratamento farmacológico , Gastropatias/tratamento farmacológico , Gastropatias/microbiologia , Triazóis/uso terapêutico
3.
Biomed Res Int ; 2016: 6481028, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27999807

RESUMO

Background. Visceral leishmaniasis (VL) caused by Leishmania infantum is endemic in the Mediterranean area. In the last decades a northward spread of the parasite has been observed in Italy. This paper describes a VL outbreak in Modena province (Emilia-Romagna, Northern Italy) between 2012 and 2015. Methods. Retrospective, observational study to evaluate epidemiological, microbiological characteristics, and clinical management of VL in patients referring to Policlinico Modena Hospital. Results. Sixteen cases of VL occurred in the study period. An immunosuppressive condition was present in 81.3%. Clinical presentation included anemia, fever, leukopenia, thrombocytopenia, and hepatosplenomegaly. Serology was positive in 73.3% of cases, peripheral blood PCR in 92.3%, and bone marrow blood PCR in 100%. Culture was positive in 3/6 cases (50%) and all the isolates were identified as L. infantum by ITS1/ITS2 sequencing. The median time between symptom onset and diagnosis was 22 days (range 6-131 days). All patients were treated with liposomal amphotericin b. 18.8% had a VL recurrence and were treated with miltefosine. Attributable mortality was 6.3%. Conclusions. VL due to L. infantum could determine periodical outbreaks, as the one described; thus it is important to include VL in the differential diagnosis of fever of unknown origin, even in low-endemic areas.


Assuntos
Surtos de Doenças , Leishmaniose Visceral/epidemiologia , Feminino , Humanos , Incidência , Itália/epidemiologia , Masculino
4.
Infection ; 44(2): 223-33, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26475482

RESUMO

PURPOSE: We investigated the clinical performance of (1 → 3)-ß-D-glucan (BG), as an early marker of invasive fungal infections (IFI), in different clinical settings. METHODS: BG serum levels were assessed by Fungitell (Associates of Cape Cod, Inc), in parallel with galactomannan (GM) when requested by clinicians. By a prospective monocentric study, 270 episodes at risk or with suspect of IFI were enrolled, namely 58 proven-probable invasive aspergillosis (IA), 27 proven invasive candidiasis (IC), 11 possible IC, 16 P.jirovecii pneumonia (PJP), 4 episodes of other IFI and 154 non-IFI controls. RESULTS: We found that (a) the BG overall sensitivity, specificity, positive predictive value and negative predictive value (NPV) were 87.9, 80.5, 76.7 and 89.9 %, respectively; (b) the highest sensitivity was found in the IC groups, followed by PJP, IA and other IFI groups; (c) an association was observed between BG kinetics and patients outcome; (d) in the IA episodes, the combination of BG or GM vs GM alone increased sensitivity from 60.0 to 83.3 % in the haematological patients; (e) false-positive BG results were related to Gram-negative infections or infusion of polyclonal IgM-enriched immunoglobulins, where high levels of BG were indeed detected. CONCLUSION: Besides strengthening its overall good clinical performance, we provide evidence that serum BG correlates with clinical outcome and that, once used in combination with GM, BG allows to enhance IFI diagnosis rate. The high sensitivity and NPV, observed in the Intensive Care Unit setting, open to BG validation as a marker for assessment of antifungal treatment.


Assuntos
Antígenos de Fungos/sangue , Fungemia/diagnóstico , Mananas/sangue , Soro/química , beta-Glucanas/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Galactose/análogos & derivados , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos , Proteoglicanas , Sensibilidade e Especificidade , Adulto Jovem
5.
J Hosp Infect ; 85(1): 73-5, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23927925

RESUMO

A Burkholderia cepacia complex outbreak occurred among ventilated non-cystic fibrosis patients in an intensive care unit (ICU) in Italy: 33 colonized and 13 infected patients were included in a retrospective study aimed at investigating factors related to clinical infection and mortality. Demographic/clinical conditions and mortality did not vary significantly between colonized and infected patients, both groups showing high mortality rates compared with the overall ICU population and similar to that observed in patients with other infections. In multivariate regression analysis, disease severity (defined by the Simplified Acute Physiology Score II) and age were the only independent predictors of early mortality (odds ratio: 1.12; 95% confidence interval: 1.02-1.26; and 1.07; 1.01-1.15, respectively).


Assuntos
Infecções por Burkholderia/microbiologia , Infecções por Burkholderia/patologia , Complexo Burkholderia cepacia/isolamento & purificação , Infecção Hospitalar/microbiologia , Infecção Hospitalar/patologia , Surtos de Doenças , Adulto , Idoso , Idoso de 80 Anos ou mais , Infecções por Burkholderia/epidemiologia , Infecções por Burkholderia/mortalidade , Infecção Hospitalar/diagnóstico , Feminino , Humanos , Unidades de Terapia Intensiva , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Análise de Sobrevida
6.
Eur J Clin Microbiol Infect Dis ; 31(5): 739-45, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-21822974

RESUMO

Bloodstream infections due to Staphylococcus aureus (BSI) are serious infections both in hospitals and in the community, possibly leading to infective endocarditis (IE). The use of glycopeptides has been recently challenged by various forms of low-level resistance. This study evaluated the distribution of MSSA and MRSA isolates from BSI and IE in 4 Italian hospitals, their antibiotic susceptibility--focusing on the emergence of hVISA--and genotypic relationships. Our results demonstrate that the epidemiology of MRSA is changing versus different STs possessing features between community-acquired (CA)- and hospital-acquired (HA)-MRSA groups; furthermore, different MSSA isolated from BSI and IE were found, with the same backgrounds of the Italian CA-MRSA. The hVISA phenotype was very frequent (19.5%) and occurred more frequently in isolates from IE and in both the MSSA and MRSA strains. As expected, hVISA were detected in MRSA with vancomycin minimum inhibitory concentrations (MICs) of 1-2 mg/l, frequently associated with the major SCCmec I and II nosocomial clones; this phenotype was also detected in some MSSA strains. The few cases of MR-hVISA infections evaluated in our study demonstrated that 5 out of 9 patients (55%) receiving a glycopeptide, died. Future studies are required to validate these findings in terms of clinical impact.


Assuntos
Bacteriemia/microbiologia , Infecção Hospitalar/microbiologia , Endocardite Bacteriana/microbiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/isolamento & purificação , Resistência a Vancomicina , Antibacterianos/farmacologia , Análise por Conglomerados , Genótipo , Humanos , Itália , Testes de Sensibilidade Microbiana , Tipagem Molecular , Staphylococcus aureus/classificação , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/genética
7.
Transplant Proc ; 43(4): 1114-8, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21620066

RESUMO

INTRODUCTION: Highly effective antiretroviral therapy in the last decade has increased the survival rates of HIV-positive patients, yielding a greater number of HIV patients suffering from liver-related disease. Liver transplantation (LT) is the only curative treatment for end-stage liver disease (ESLD) associated or not with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: From June 2003 to September 2010, 23 patients underwent cadaveric donor LT for ESLD at our institution. Inclusion criteria followed the Italian Protocol for LT in HIV-positive patients. Immunosuppressive regimens were based on cyclosporine or tacrolimus, eventually switched to Rapamycin. RESULTS: The median CD4 T-cell count was 275/mmc (range=119-924). All patients were affected by ESLD, which was associated with HCC in 14 cases. Ten patients were within the Milan criteria and four patients exceeded them but were within the San Francisco criteria. Conversion from calcineurin inhibitors (CNI) to rapamycin occurred in ten cases. Hepatitis C virus (HCV) recurrence occurred in 13/21 HCV-positive patients. Acute cellular rejection occurred in eight patients with one developing chronic cellular rejection. Overall patient and graft survivals at 80 months were 50% and 45% respectively. DISCUSSION: LT in HIV-positive patients is a feasible procedure, even if in our experience was burdened by a greater incidence of complications including HCV recurrence and infection compared with HIV-negative patients.


Assuntos
Carcinoma Hepatocelular/cirurgia , Doença Hepática Terminal/cirurgia , Infecções por HIV/complicações , Hepatite C Crônica/cirurgia , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Adulto , Terapia Antirretroviral de Alta Atividade , Contagem de Linfócito CD4 , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/diagnóstico , Ciclosporina/uso terapêutico , Substituição de Medicamentos , Doença Hepática Terminal/complicações , Doença Hepática Terminal/diagnóstico , Feminino , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto , HIV/genética , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Hepatite C Crônica/complicações , Hepatite C Crônica/diagnóstico , Hospitais Universitários , Humanos , Imunossupressores/uso terapêutico , Itália , Estimativa de Kaplan-Meier , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/diagnóstico , Transplante de Fígado/efeitos adversos , Transplante de Fígado/imunologia , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Recidiva , Índice de Gravidade de Doença , Sirolimo/uso terapêutico , Tacrolimo/uso terapêutico , Fatores de Tempo , Resultado do Tratamento , Carga Viral
8.
Transpl Infect Dis ; 13(5): 501-6, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21414117

RESUMO

Although human immunodeficiency virus (HIV) infection has been a major global health problem for almost 3 decades, with the introduction of highly active antiretroviral therapy in 1996 and effective prophylaxis and management of opportunistic infections, mortality from acquired immunodeficiency syndrome has decreased markedly. In developed countries, this condition is now being treated as a chronic condition. As a result, rates of morbidity and mortality from other medical conditions leading to end-stage liver, kidney, and heart disease are steadily increasing in individuals with HIV. Because the definitive treatment for end-stage organ failure is transplantation, the demand for it has increased among HIV-infected patients. For these reasons, many transplant centers have eliminated HIV infection as a contraindication to transplantation, as a result of better patient management and demand.


Assuntos
Infecções por HIV/complicações , Transplante de Rim , Transplante de Fígado , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Infecções por HIV/tratamento farmacológico , Humanos , Falência Hepática/terapia , Masculino , Pessoa de Meia-Idade , Seleção de Pacientes , Insuficiência Renal/terapia , Resultado do Tratamento
9.
Am J Transplant ; 10(10): 2252-62, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20486905

RESUMO

We designed a randomized trial to assess whether the early withdrawal of cyclosporine (CsA) followed by the initiation of everolimus (Evr) monotherapy in de novo liver transplantation (LT) patients would result in superior renal function compared to a CsA-based immunosuppression protocol. All patients were treated with CsA for the first 10 days and then randomized to receive Evr in combination with CsA up to day 30, then either continued on Evr monotherapy (Evr group) or maintained on CsA with/without mycophenolate mofetil (CsA group) in case of chronic kidney disease (CKD). Seventy-eight patients were randomized (Evr n = 52; CsA n = 26). The 1-year freedom from efficacy failure in Evr group was 75% versus 69.2% in CsA group, p = 0.36. There was no statistically significant difference in patient survival between the two groups. Mean modification of diet in renal disease (MDRD) was significantly better in the Evr group at 12 months (87.7 ± 26.1 vs. 59.9 ± 12.6 mL/min; p < 0.001). The incidence of CKD stage ≥ 3 (estimated glomerular filtration rate < 60 mL/min) was higher in the CsA group at 1 year (52.2% vs. 15.4%, p = 0.005). The results indicate that early withdrawal of CsA followed by Evr monotherapy in de novo LT patients is associated with an improvement in renal function, with a similar incidence of rejection and major complications.


Assuntos
Inibidores de Calcineurina , Ciclosporina/efeitos adversos , Imunossupressores/efeitos adversos , Transplante de Fígado/efeitos adversos , Insuficiência Renal/prevenção & controle , Sirolimo/análogos & derivados , Adulto , Ciclosporina/administração & dosagem , Dislipidemias/tratamento farmacológico , Dislipidemias/etiologia , Everolimo , Feminino , Humanos , Imunossupressores/administração & dosagem , Testes de Função Renal , Masculino , Pessoa de Meia-Idade , Sirolimo/uso terapêutico
10.
Am J Transplant ; 9(10): 2429-34, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19656133

RESUMO

Pharmacokinetic (PK) interactions between protease inhibitors (PI(s)) and immunosuppressive agents (IS) are critical elements in the management of HIV-infected patients who undergo liver transplantation (LT(x)). The primary objective of this study was to evaluate the decreases in IS dosages necessary to maintain an appropriate therapeutic window (TW) after initiating PI-based antiretroviral therapy regimens post-LT(x). Single-center, PK cross-sectional study of consecutive HIV-infected adult patients who underwent LT(x) was done. Blood trough concentrations (C(t)) of IS were obtained using a commercial MEIA test; plasma C(t) of PI(s) were measured using HPLC. Twelve consecutive HIV-infected adult patients (11 males, 1 female) were enrolled. More rapid increases in IS plasma C(t) were observed 48 h after initiating ritonavir (RTV)-boosted PI therapy post-LT(x) than when using unboosted PI(s). Seven patients developed acute renal failure. The median fold decrease in IS dosages required to regain IS concentrations that were in the TW was 7.5 (range 6-14) after resuming boosted PI(s) and 2.9 (range 2-4) after unboosted PI(s). The overall median time necessary to reach IS TW after dose adjustment was 3.5 days (range 0-15). Unboosted PI(s) exhibited lesser PK interactions with IS than did RTV-boosted PI(s) and were thus more amenable to use in the post-LT(x) setting.


Assuntos
Infecções por HIV/tratamento farmacológico , Inibidores da Protease de HIV/uso terapêutico , Imunossupressores/uso terapêutico , Transplante de Fígado , Adulto , Cromatografia Líquida de Alta Pressão , Estudos Transversais , Relação Dose-Resposta a Droga , Feminino , Infecções por HIV/cirurgia , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/sangue , Humanos , Imunossupressores/administração & dosagem , Masculino , Pessoa de Meia-Idade
11.
Am J Transplant ; 9(7): 1690-7, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19519818

RESUMO

The unique phenomenon of human herpesvirus-6 (HHV-6) chromosomal integration (CIHHV-6) may account for clinical drawbacks in transplant setting, being misinterpreted as active infection and leading to unnecessary and potentially harmful treatments. We have investigated the prevalence of CIHHV-6 in 205 consecutive solid organ (SO) and allogeneic stem cell transplant (alloSCT) Italian patients. Fifty-two (38.5%) of 135 solid organ transplant (SOT) and 16 (22.8%) of 70 alloSCT patients resulted positive for plasma HHV-6 DNA by real-time polymerase chain reaction. Seven SOT and three alloSCT patients presented HHV-6-related diseases, requiring antivirals. Two further patients (0.9%) were identified, presenting high HHV-6 loads. The quantification of HHV-6 on hair follicles disclosed the integrated state, allowing the discontinuation of antivirals. Before starting specific treatments, CIHHV-6 should be excluded in transplant patients with HHV-6 viremia by the comparison of HHV-6 loads on different fluids and tissues. Pretransplantation screening of donors and recipients may further prevent the misdiagnosis of CIHHV-6.


Assuntos
Herpesvirus Humano 6/genética , Herpesvirus Humano 6/patogenicidade , Transplante de Células-Tronco , Transplantes , Integração Viral/genética , Adulto , Estudos de Coortes , DNA Viral/sangue , DNA Viral/genética , Herpesvirus Humano 6/isolamento & purificação , Herpesvirus Humano 6/fisiologia , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Infecções por Roseolovirus/diagnóstico , Infecções por Roseolovirus/etiologia , Infecções por Roseolovirus/virologia , Transplante de Células-Tronco/efeitos adversos , Transplante Homólogo , Transplantes/efeitos adversos , Viremia/diagnóstico , Viremia/etiologia , Viremia/virologia
12.
Infection ; 37(3): 250-5, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19471855

RESUMO

BACKGROUND: No data are available on the use of atazanavir (ATV) in patients with end-stage liver disease (ESLD), and guidelines discourage its use in this setting. The objective of our study was to evaluate the efficacy and safety of unboosted ATV in patients infected with HIV and suffering from ESLD who had been screened for orthotopic liver transplantation (OLT(x)). PATIENTS AND METHODS: This was a single-arm, 24-week pilot study. Atazanavir-naïve patients undergoing a highly active antiretroviral therapy were switched to ATV 400 mg daily plus two non-thymidine nucleoside reverse transcriptase inhibitors. RESULTS: Fifteen patients (ten males and five females, age range 36-59 years) were enrolled in the study. Of these, 11 (73%) had a baseline CD4 cell count > 200 microl(-1), and 12 had undetectable plasma HIV-RNA. 12 subjects (80%) were able to remain on ATV until week 24 (n = 10) or transplantation (n = 2). At the end of the study, the median CD4 cell count was 340 microl(-1) , and nine of the ten patients had undetectable RNA. During the study period, two patients received a transplant, two died of intracerebral hemorrhage and lactic acidosis, respectively, and one discontinued ATV. Among the ten patients completing the 24-week study, no significant changes from baseline were observed for most of the liver function markers, with the exception of unconjugated bilirubin (from 1.15 mg/dl to 1.32 mg/dl, p = 0.047). CONCLUSIONS: Unboosted ATV treatment did not worsen liver disease and was able to maintain or gain immunovirological eligibility for OLT(x) in all patients, with a limited effect on unconjugated bilirubin. These results suggest that ATV is an easy-to-use drug in patients with ESLD.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Falência Hepática/complicações , Oligopeptídeos/uso terapêutico , Piridinas/uso terapêutico , Adulto , Fármacos Anti-HIV/efeitos adversos , Terapia Antirretroviral de Alta Atividade , Sulfato de Atazanavir , Contagem de Linfócito CD4 , Feminino , Seguimentos , Infecções por HIV/imunologia , Humanos , Falência Hepática/mortalidade , Testes de Função Hepática , Transplante de Fígado , Masculino , Pessoa de Meia-Idade , Oligopeptídeos/efeitos adversos , Projetos Piloto , Piridinas/efeitos adversos , Resultado do Tratamento , Carga Viral
13.
Transplant Proc ; 40(6): 1986-8, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18675108

RESUMO

The aim of this study was to compare the incidence of ventilator-associated pneumonia (VAP) and clinical outcome among patients undergoing orthotopic liver transplantation (OLT) admitted to our surgical intensive care unit (ICU). Patients with an ICU stay longer than 4 days who had undergone surgery within 48 hours of admission were included in the study. Patients were subdivided into a liver transplant group (OLT) and no-liver transplant group (noLT). Diagnosis of VAP was based on microbiological data with a positive culture from a sample collected >or=48 hours after admission. VAP was defined as early if the positive culture occurred within the 4th day of admission, and late if after the 4th day. Three hundred seventy-three noLT and 71 OLT patients showed no differences in sex, mean severity score on admission (SAPS II), length of stay, and outcomes. The incidence of VAP was also similar in the 2 groups (27.3% in the noLT group vs 25.3% in the OLT group). Both in the OLT and noLT groups, the VAP patients showed higher (P< .05) SAPS II scores on admission, length of ICU stay, and mortality rates than the non-VAP patients, without any difference between the 2 groups. VAP is a frequent complication in ICU surgical patients, particularly those with high severity scores on admission. In an ICU surgical population, liver transplantation per se does not seem to increase the patients' risk either for VAP acquisition or for bad outcomes.


Assuntos
Transplante de Fígado/efeitos adversos , Pneumonia Associada à Ventilação Mecânica/epidemiologia , Procedimentos Cirúrgicos Operatórios/efeitos adversos , Humanos , Incidência , Unidades de Terapia Intensiva , Complicações Pós-Operatórias/epidemiologia , Estudos Retrospectivos , Resultado do Tratamento
14.
Eur J Surg Oncol ; 34(4): 422-7, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17590564

RESUMO

INTRODUCTION: Several reports have shown the effectiveness of liver transplantation (LT) as a therapeutic option in HIV-patients affected by end-stage liver disease. HCC on cirrhosis is another major indication for LT. However, no reports, to our knowledge, have been published as yet addressing the important questions of indications and outcome of LT in HIV-patients with HCC, mainly because of concerns regarding a more aggressive course of HCC with respect to HCC seen in HIV-negative individuals. METHODS: The aim of this report is to focus on indications, preliminary results and complications of LT in a group of 7 HIV-patients who underwent LT at our department for HCC on cirrhosis. RESULTS: Indications to listing HIV-patients were HCC using the internationally accepted Milan criteria. All patients were HBV-and/or HCV-infected. The mean CD4+ cell-count was 249 (range 144-353), and the HIV-RNA load was undetectable in all but one case. After a mean follow-up period of 232days (range 33-774), no recurrence of HCC was seen; one patient died. CONCLUSION: Characteristics of the study protocol, the patients, virological and immunological features, tumor stage and pre-transplantation treatment, complications and survival are herein described in an effort to provide new insights into methodology for an aggressive management of HCC in HIV patients, and possibly give a greater chance of cure.


Assuntos
Carcinoma Hepatocelular/cirurgia , Infecções por HIV/complicações , Neoplasias Hepáticas/cirurgia , Transplante de Fígado , Adulto , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/mortalidade , Estudos de Viabilidade , Humanos , Cirrose Hepática/complicações , Neoplasias Hepáticas/complicações , Neoplasias Hepáticas/mortalidade , Masculino , Pessoa de Meia-Idade
15.
Transplant Proc ; 39(6): 1947-9, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17692662

RESUMO

The objective of the study was to assess the incidence, risk factors, and survival of gram-positive bloodstream infections (GP-BSI(s)) among liver transplant recipients during the first year after transplantation. Between October 2000 and September 2006, 42 episodes of GP-BSI(s) occurred in 205 patients with an overall incidence of 0.20 episodes/patient. Coagulase-negative staphylococci were detected in 45.2% of cases, Enterococcus species in 42.9% (E faecalis, eight; E faecium, seven; E avium, two; E gallinarum, one) and Staphylococcus aureus in 11.9%. Retransplantation was the only independent risk factor for GP-BSI (odds ratio [OR], 0.253; 95% confidence interval (CI), 0.089 to 0.715; P = .009). Thirty-day mortality rate was 28.5% and S aureus infections were related to a poorer outcome. It is noteworthy that all the isolates of S aureus were methicillin-resistant. Ampicillin was inactive against all the strains of E faecium and 50% of E avium isolates, but active against all E faecalis and E gallinarum strains. All the isolates were glycopeptide-susceptible. No significant differences in mortality rate were observed in relation to sex, etiologies of end-stage liver disease, cytomegalovirus infection/reinfection, type of donor, rejection, or retransplantation. GP-BSI, the only independent risk factor for death (OR, 0.262; 95% CI, 0.106 to 0.643; P = .003), reduced the survival rate by 26% in the first year posttransplant. In conclusion, GP-BSI(s) impact significantly on morbidity and mortality posttransplant, particularly among retransplantations. Control measures are required to reduce the incidence of GP-BSI(s) in liver transplant recipients. These findings must be considered when empirical antimicrobial therapy is indicated while awaiting blood-culture results.


Assuntos
Infecções por Bactérias Gram-Positivas/sangue , Transplante de Fígado/efeitos adversos , Adulto , Enterococcus/isolamento & purificação , Feminino , Humanos , Incidência , Hepatopatias/classificação , Hepatopatias/cirurgia , Transplante de Fígado/mortalidade , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Análise de Sobrevida
16.
Leukemia ; 21(3): 578-81, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17215858
17.
Transplant Proc ; 38(4): 1083-5, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16757271

RESUMO

This report describes a case of pulmonary tuberculosis in a liver transplant patient without a history of previous exposure to Mycobacterium tuberculosis (MTB) complex. Prior to transplantation, the tuberculin skin test was negative and the QuantiFERON-TB Gold (QFT Gold), an interferon gamma-based blood test, was negative before and after transplant including a period beginning on postoperative day 55 when the patient developed a febrile illness with an interstitial infiltrate and pleural effusion that was unresponsive to broad-spectrum antibiotic therapy. Empiric treatment with isoniazid, ethambutol, and levofloxacin resulted in resolution of the clinical symptoms. A sputum culture grew MTB on postoperative day 87. This case illustrates the need for caution when QFT Gold is used as diagnostic tool for latent tuberculosis during the pretransplant assessment. Further studies evaluating the usefulness of QFT Gold and other interferon gamma tests in posttransplantation active infection are warranted.


Assuntos
Transplante de Fígado , Complicações Pós-Operatórias/microbiologia , Tuberculose/diagnóstico , Adulto , Anemia/etiologia , Humanos , Interferon gama/sangue , Masculino , Mycobacterium tuberculosis , Teste Tuberculínico
18.
Transplant Proc ; 38(4): 1138-40, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16757288

RESUMO

The pharmacokinetic interaction between highly active antiretroviral therapy (HAART) and immunosuppressive drugs is a critical element in the management of patients with human immunodeficiency virus infection who undergo orthotopic liver transplantation (OLT). We describe the effect of the coadministration of Amprenavir/Ritonavir (APV/r) and FosAmprenavir (FosAPV) on cyclosporine (CsA) concentrations in two patients receiving OLT for end-stage liver disease due to hepatitis C Virus. Patient 1, who was maintained on 300 mg CsA twice a day with a trough concentration (C(trough)) around 250 ng/mL, restarted HAART 12 days after transplantation with 300 mg APV/r twice a day with corresponding APV C(trough) of 5293 ng/mL and RTV C(trough) of 186 ng/mL. Forty-eight hours after initiation of HAART, C(trough) of CsA was 1200 mg/mL, so it was necessary to reduce the CsA dosage 12-fold (50 mg every day) to achieve a therapeutic effect. In Patient 2, who was maintained on 300 mg CsA twice a day and a corresponding C(trough) of 400 ng/mL, HAART was restarted 12 days post-OLT with FosAPV 1400 mg twice a day. After 48 hours C(trough) of CsA was around 600 ng/mL and C(trough) of FosAPV, 1221 ng/mL. In this case it was necessary to reduce the CsA administration 3.5-fold (175 mg every day). In conclusion, therapeutic drug monitoring was necessary to monitor HAART and CsA post-OLT to prevent toxicity due to both therapies. The use of FosAPV without ritonavir boostering is sufficient to maintain adequate CsA blood concentrations, avoiding any event of toxicity.


Assuntos
Fármacos Anti-HIV/farmacocinética , Carbamatos/farmacocinética , Infecções por HIV/tratamento farmacológico , Imunossupressores/farmacocinética , Transplante de Fígado/imunologia , Organofosfatos/farmacocinética , Sulfonamidas/farmacocinética , Adulto , Fármacos Anti-HIV/uso terapêutico , Carbamatos/uso terapêutico , Furanos , Hepatite C/cirurgia , Humanos , Imunossupressores/uso terapêutico , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Organofosfatos/uso terapêutico , Sulfonamidas/uso terapêutico , Resultado do Tratamento
19.
Clin Microbiol Infect ; 12(1): 75-80, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16460550

RESUMO

The epidemiological and antifungal susceptibility data for 94 episodes of candidaemia in an Italian tertiary-care hospital between January 2000 and August 2003 were evaluated by prospective laboratory-based surveillance. The incidence of fungaemia was 0.90 episodes/10 000 patient-days, and the most common species isolated were Candida albicans (40.4%), Candida parapsilosis (22.3%), Candida tropicalis (16.0%) and Candida glabrata (12.8%). Among 24 patients who received antifungal prophylaxis, non-albicans Candida spp. were more prevalent than C. albicans (p 0.012). The 30-day mortality rate was high (38.2%), particularly for haematological (71.4%) and solid-organ transplant patients (50.0%), and in individuals with C. tropicalis and C. glabrata bloodstream infections (60.0% and 50.0%, respectively). In-vitro susceptibility tests demonstrated that 95% of the isolates were susceptible to amphotericin B (MIC < 2 mg/L), 98.1% to posaconazole (MIC < 1 mg/L), 95.8% to flucytosine (MIC < 32 mg/L) and fluconazole (MIC < 64 mg/L), and 94.7% to itraconazole (MIC < 1 mg/L). Posaconazole was active (MIC 0.5 mg/L) against all three isolates of Candida krusei, which had reduced susceptibility to both fluconazole and itraconazole. Overall, non-albicans Candida spp. accounted for 60% of the episodes of candidaemia, which could be related to the use of antifungal prophylaxis. Resistance is still uncommon in Candida spp. recovered from blood cultures. The in-vitro activity of posaconazole is encouraging, and this agent could play an important role in the management of invasive candidiasis, including episodes caused by inherently less susceptible species such as C. krusei.


Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Candidíase/epidemiologia , Fungemia/epidemiologia , Hospitais Universitários , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Candida/classificação , Candida/isolamento & purificação , Candidíase/microbiologia , Candidíase/mortalidade , Criança , Pré-Escolar , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Farmacorresistência Fúngica , Feminino , Fungemia/microbiologia , Fungemia/mortalidade , Humanos , Lactente , Recém-Nascido , Itália/epidemiologia , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Prevalência , Triazóis/farmacologia
20.
Dig Liver Dis ; 38(6): 429-33, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16169779

RESUMO

Although advances in immunosuppressive therapy have led to increased survival of solid organ transplantation recipients, it is well established that current protocols have been associated with an increased risk of developing tissue-invasive infections. In particular, cytomegalovirus still represents an important cause of morbidity. We report a case of cytomegalovirus infection involving the graft ileum with documented necrotising enteritis that developed after small bowel transplantation. The patient, a 56-year-old Caucasian female with a postsurgery short bowel syndrome, underwent a small bowel transplantation. Immunosuppression was maintained by combination of tacrolimus, steroids and daclizumab. Both the donor and the recipient were serologically negative for cytomegalovirus IgG. Nevertheless, ganciclovir prophylaxis was given for 21 days after surgery, as standard procedure. On hospital day 174, routine pp65 antigenaemia resulted positive (14/200,000 peripheral blood leukocytes). The patient was asymptomatic and preemptive ganciclovir therapy was instituted. In the following 3 days, due to a cytomegalovirus antigenaemia increase, ganciclovir was changed to foscarnet with subsequent virological response (7/200,000 peripheral blood leukocytes, on day 181). Two days later, the patient complained of acute abdominal pain and she underwent surgery for the diagnosis. Since the intraoperative findings consisted of a diffuse acute purulent peritonitis, the intestinal graft, together with native rectum, was removed. Biopsy specimens showed evidence of tissue-invasive cytomegalovirus infection. Postsurgery, the patient developed septic shock and died on day 198 as a consequence of multiple organ failure.


Assuntos
Infecções por Citomegalovirus/patologia , Enterite/patologia , Íleo/transplante , Fosfoproteínas/imunologia , Síndrome do Intestino Curto/patologia , Proteínas da Matriz Viral/imunologia , Idoso , Citomegalovirus/imunologia , Evolução Fatal , Feminino , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...